• Filana Therapeutics announced published preclinical simufilam findings as it prepares a Phase 2a trial in tuberous sclerosis complex-related epilepsy.
• Patient screening for the planned trial is expected to begin by the first quarter of 2027.
• Results published in Cells showed reduced cellular stress responses and restored mitochondrial function in engineered human cells.
• The findings suggest a mechanism distinct from direct mTOR inhibition; clinical studies are needed to establish seizure benefits in patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854802) on October 28, 2026, and is solely responsible for the information contained therein.